Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Newly Diagnosed ALL in Infants (CCG-1953)
NCT00002785Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Jul 1996
- Primary completion
- Aug 2000
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands, Replacement Enzymes
- Countries
- 3
01
Overview
A Phase 2 trial of cytarabine, asparaginase escherichia coli, cyclophosphamide, daunorubicin, dexamethasone in acute lymphoblastic leukemia (ALL), sponsored by Children's Oncology Group. Started Jul 1996; status: completed.
02
Drugs
cytarabineasparaginase escherichia colicyclophosphamidedaunorubicindexamethasone
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00002785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002785.